Log in

NASDAQ:AMRNAmarin Stock Price, Forecast & News

$7.24
-0.04 (-0.55 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.49
Now: $7.24
$7.35
50-Day Range
$4.78
MA: $6.83
$8.26
52-Week Range
$3.95
Now: $7.24
$26.12
Volume13.34 million shs
Average Volume10.17 million shs
Market Capitalization$2.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.83
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More
Amarin logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$429.76 million
Book Value$1.46 per share

Profitability

Net Income$-22,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.79 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Amarin (NASDAQ:AMRN) Frequently Asked Questions

How has Amarin's stock been impacted by COVID-19 (Coronavirus)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRN stock has decreased by 42.4% and is now trading at $7.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amarin?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amarin.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amarin.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company had revenue of $155 million for the quarter, compared to analysts' expectations of $150.06 million. Amarin had a negative net margin of 3.67% and a negative return on equity of 4.05%. The company's revenue for the quarter was up 111.5% on a year-over-year basis. During the same period last year, the business earned ($0.05) earnings per share. View Amarin's earnings history.

What guidance has Amarin issued on next quarter's earnings?

Amarin issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $650-700 million, compared to the consensus revenue estimate of $695.43 million.

What price target have analysts set for AMRN?

13 Wall Street analysts have issued 1-year target prices for Amarin's stock. Their forecasts range from $4.00 to $51.00. On average, they expect Amarin's share price to reach $17.23 in the next year. This suggests a possible upside of 138.0% from the stock's current price. View analysts' price targets for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin reported encouraging fourth-quarter results, wherein both earnings and sales beat estimates. Amarin’s sole marketed drug Vascepa has been on a strong growth trajectory for the last four years. The drug’s recent label expansion for cardiovascular indication looks promising. The growth trend for Vascepa is expected to continue in 2020. The company is expanding its sales force and start promotional programs to create awareness for Vascepa’s expanded label. These initiatives are likely to drive sales higher. The company is looking to get approval for the drug in additional countries. However, Amarin is over-dependent on Vascepa for its growth. Any setback to its commercialization plans will have an unfavorable impact. Competition is also rising in the targeted market. Shares have underperformed the industry in the past year." (3/5/2020)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)

Has Amarin been receiving favorable news coverage?

Media stories about AMRN stock have been trending extremely negative on Monday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutAmarin.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), Alibaba Group (BABA), Gilead Sciences (GILD), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (1.33%), Federated Hermes Inc. (0.89%), BlackRock Inc. (0.80%), Clearbridge Investments LLC (0.57%), Morgan Stanley (0.42%) and Pictet Asset Management Ltd. (0.35%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View institutional ownership trends for Amarin.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Atom Investors LP, Cormorant Asset Management LP, Stonepine Capital Management LLC, BlackRock Inc., Ensign Peak Advisors Inc, Chartwell Investment Partners LLC, and First Midwest Bank Trust Division. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Lars Ekman, and Michael Wayne Kalb. View insider buying and selling activity for Amarin.

Which institutional investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, First Manhattan Co., Clearbridge Investments LLC, BNP Paribas Arbitrage SA, Pictet Asset Management Ltd., AGF Investments Inc., Squarepoint Ops LLC, and FDx Advisors Inc.. View insider buying and selling activity for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $7.24.

How big of a company is Amarin?

Amarin has a market capitalization of $2.79 billion and generates $429.76 million in revenue each year. The biopharmaceutical company earns $-22,650,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.